TRINETRA › Sectors › Healthcare
Sakar Healthcare Limited (SAKAR) — share price, P/E and fundamentals
Sakar Healthcare Limited (NSE: SAKAR) closed at ₹939.00 on 30 Oct 2026, +167.1% over one year, against a 52-week range of ₹350.10 – ₹1,229.85.
In the quarter ended 30 Sept 2026 (consolidated, filed 23 Oct 2026) it reported revenue of ₹87 cr and net profit of ₹11 cr, a 12.9% net margin; revenue grew 51.9% and profit grew 199.0% year on year.
On four consecutive filed quarters its trailing P/E is 48.7; since 16 May 2025 its own P/E has ranged from 38.2 to 73.4 (median 48.4), and today's reading is higher than 52% of those 360 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 13.1%, ROCE 18.2%, debt-to-equity 0.13, Piotroski F-score 8 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 52% of 64 sector peers; PBT margin higher than 53% of 64 sector peers; ROE higher than 45% of 64 sector peers.
Key figures
| Last close | ₹939.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -16.8% / +49.3% / +167.1% |
| 52-week low – high | ₹350.10 – ₹1,229.85 |
| Market capitalisation | ₹2,089 cr |
| Trailing P/E | 48.7 |
| Price / book | 6.04 |
| EV / EBITDA | 23.0 |
| Earnings yield | 2.1% |
| TTM EPS | ₹19.27 |
| TTM net profit | ₹43 cr |
| Quarter revenue | ₹87 cr |
| Quarter net profit | ₹11 cr |
| Net margin | 12.9% |
| Revenue growth (YoY) | +51.9% |
| Profit growth (YoY) | +199.0% |
| Return on equity | 13.1% |
| ROCE | 18.2% |
| Debt / equity | 0.13 |
| Current ratio | 1.34 |
| Free cash flow | ₹1 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹11.1 cr |
Against Healthcare peers
| Metric | SAKAR | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.93 | 12.89 | 52 |
| PBT margin | 18.33 | 17.68 | 53 |
| ROE | 13.07 | 13.87 | 45 |
| ROCE | 18.22 | 17.26 | 59 |
| Debt / equity | 0.13 | 0.11 | 54 |
| FCF margin | 0.88 | -0.87 | 53 |
| Cash conversion | 1.09 | 1.25 | 42 |
| Trailing P/E | 48.74 | 43.26 | 55 |
Questions
What is the P/E ratio of Sakar Healthcare Limited?
Sakar Healthcare Limited's trailing P/E is 48.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 16 May 2025 its P/E has ranged 38.2–73.4.
What were Sakar Healthcare Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Sakar Healthcare Limited reported revenue of ₹87 cr and net profit of ₹11 cr (consolidated), filed with the exchange on 23 Oct 2026.
What is Sakar Healthcare Limited's ROE?
Return on equity is 13.1% based on the balance sheet dated 30 Sept 2026.
Does Sakar Healthcare Limited have debt?
Debt-to-equity is 0.13 on the balance sheet dated 30 Sept 2026.
What is SAKAR's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SAKAR traded between ₹350.10 and ₹1,229.85.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.